Soleno Therapeutics Inc (6XC.SG)
| Previous Close | 40.78 |
| Open | 41.06 |
| Bid | 41.86 x N/A |
| Ask | 43.26 x N/A |
| Day's Range | 40.72 - 41.82 |
| 52 Week Range | 3.37 - 47.40 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for the Prader-Willi syndrome communityREDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today launched a groundbreaking initiative in honor of Prader-Willi Syndrome (PWS) Awareness Day. The campaign
- GlobeNewswire
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 and Recent Corporate Highlights Closed on approximately $158.7 million underwritten public offering of 3,450,000 shares of common stock at a public offering
- GlobeNewswire
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $46.00 per share. The gross proceeds of the public offering are expected to be approximately $138.0 million, before deducting under
